
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc has demonstrated a strong upward trajectory with a 19% year-over-year growth in kidney surveillance volumes, reflecting the increasing demand for its testing services. The company has strategically expanded its sales force by approximately 50%, positioning itself for enhanced market penetration and revenue generation, with new representatives expected to ramp up within 6-9 months. Additionally, CareDx aims for an EBITDA margin target of 20% by 2027, along with a goal to increase its incremental cash target by over $100 million, indicating strong financial planning and growth potential.
Bears say
CareDx Inc faces significant concerns stemming from frequent changes in management over the past three years, which may impact the company's strategic direction and operational stability. Additionally, there are doubts regarding the company's ability to successfully commercialize new diagnostic solutions that are crucial for its growth, potentially hindering revenue generation. The company's uncertainty surrounding potential increases in Medicare reimbursement limits for kidney tests further complicates its revenue outlook, as increased testing limits may not materialize as hoped.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares